MaaT Pharma schedules FDA Pre-IND for MaaT034
MaaT Pharma says it has scheduled an FDA Pre-IND meeting for MaaT034 in Oct 2026, focused on CMC. The company targets first-in-human study start in late 2027, pending regulatory clearance and funding.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.